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Tlte background of this thesis is presented in the introductory chapters and stafts with a brief
history of neuromuscular relaxants. It is fbllowed by a short description of the neuromuscular
physiology and pharmacology in chapters 2 and 3, respectively. In chapter 4 the aim of the thesis
is presented:
To irtvestigete tlrc dose-cortcetÍrctíiott-effect relatiortship of sonrc rtort-depolarisirtg
rrtttscle relaxarÍs and their irÍeractiorts.
Sciertific studies
In clwpter 5 the pharmacodynamics of vecuronium are compared to those of rapacuroniunr (Org
9487). The time course of action of equipotent doses of rapacuronium and vecuronium is
measured, Also their mutual interaction when given in successioll is investigated. Sixty ASA I-II
patients were anaesthetised with thiopentone, Íèntanyl, halothane and nitrous oxide and assigned
randomly to fbur groups. Each patient received an initial dose of either vecuronium or
rapacuroniurn Íbllowed by maintenance doses of either vecuronium or rapacurcniuln (initial
dose/rnai nten ance do se : rapac uroni Ll rr/rapac uron i u m, vecuron i unVrapac uroni um,
rapacuronium/vecuronium ancl vecuroniurn/vecuroniurn). The time coLlrse of action was
measured mechanomyographically, deterrnining the duration of the single twitch untrl257o
recovery (D[IR2-5). The onset time of an initial dose of rapacuronium was shorter than that of an
initial dose of vecuronium [96 and 203 sec, respectively; P<0.001]. The D[IR25 of the initial dose
of rapacuronium was less than half that of vecuronium [0.7+2.8 and 28.8+6.1 min, respectively:
P<0.0011. The DUR2s of the first and second maintenance doses of rapacuronium were shorter
tlran those of vecuronium (rapacuronium/rapacuronium:7 .3t2.8 and 8.5+2.4 min;
vecuronium/rapacuronium: 12.7+3.3 and 11.5+3.5 min, vs rapacuronium/vecuroniurn: 16.4+4.5
and20.6t4.7 min; vecuronium/vecuroniurn: 18.8+3.0 and 20.1+3.8 min, respectively; P<0.05).
An initial dose of vecuronium prolonged the DUR25 of the Í'irst and second maintenance doses of
rapacuroniurn significantly (P<0.05). In the rapacuroniunr/rapacuronium group an individual
increase in DlIRz.s was observed with increasing maintenance dose administration.
From these results it can be concluded that rapacuronium is a muscle relaxant with a shorter
onset time and shofter duration of action than vecuronium. Maintenance doses of rapacuronium
are also shorter acting than equipotent rnaintenance doses of vecuronium, irrespective of which
relaxant is given init ial ly.
In clnpter ó the pharmacokinetic behaviour of the 3-desacetyl rnetabolite of rapacuronium,
Org 9488, is investigated in man (n=7). Addit ional ly, in two separate studies the pharma-
cokinetic-phannacodynamic (PK-PD) relat ionship of rapacuronium (n=10) and Org 9488
(n=7) were investigated. The reason to study this is that the 3-desacetyl metaboli te of
rapacuronium, Org 9488, also exerts neurornuscular blocking activi ty. This rnay become
apparent af ier prolonged maintenance of relaxation with rapacuronium. Investigation of the
PK-PD relationship of both rapacuronium and its rnetabolite rnay offer some insight in how
they interact at the effect site.
Similar protocols were used for three study groups regarding the anaesthetic technique, blood
ancl urine sampling, phannacokinetic and PK/PD analysis. The time course of action was
measured mechanomyographical ly at the adductor pol l icis muscle. The median clearance of
rapacuronium was 7.28 ml.kg-l .min-r with an excretion fract ion in the urine of 6.2Vo.The
clearance of Org 9488 (stucl iecl in two groups) was 1.28 ancl 1.06 ml.kg-r.min-r with an
excretion f iact ion in the urine of 5L9Va and 53.57o, respectively. The median rate constant of
transport between plasma and the biophase (k.o) of rapacuronium (0.449 rnin-r; is markeclly
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larger than fbr Org 9488 (0.105 min-r).  The modeled concentrat ion in the biophase i l  50Vo
effect (ECso) o. 
I p.:r.ure of porency is higrrer Íbr rapacuronium (4.70 Fg.;l:i;;;1i;ór,9488 (1.83 ptg.ml- ' ; .  I t  is conclucled that thó clearancó, ks6 and EC56 of rapacuronium are
consistent witlr its rapid onset ancl short to intermecliate duration. The lower clearance of the
metaboli te wil l  gradually prolong the t ime course of the neuromuscular blockacle clurins
maintenance with rapacuronium.
ht chapter 7 the PK-PD clata of vecuronium, rapacuronium ancl their active metabolites were
used to simulate the interaction between vecuronium ancl rapacuronium. These results were
used Íbr comparison to the clata frorn the clinical, experimental, pharmacodynamic stuclypresented in chapter 5' The inÍbrmation fiom these sinulations may contribute to theidentiÍication of the type of interaction. Hypothetically the type of interaction is saicl to have
an addit ive character.
The clinical study. results from chapter 5 ancl 6 are used. pK-pD clata of vecuroniurn weretaken f ionl a publ ished stucly ancl personal communication with the investigator of this stucly(Prof. Caldwell ,  San Francisco).
The DUR:5 of a maintenance close as clescribed in chapter 5 (DURz5) was recalculatecl as apercentage of the mean DUR:s of the init ial  close to account Íor interindiviclual dif Íerences. A
modif icat ion of Sheiner's method was used for PK-PD modeling. Simulat ions werepertbrrned by the computer program PKPD to clescribe the concèntration-rime profile in t6e
compartments, including the effect compartment, and the t ime course of neurornuscular block.The simulat ions reproducecl the experimental results satisfactori ly. Especial ly in the group
rapacuroniutn/rapacuronium DURz-s could only be sirnulated satistactàri ly i f  the inluence oft l te act ive rnetaboli te of rapacuronium, 3-desaóetyl-rapacuronium lorg giss), was taken into
account'  The contr ibution of the active rnetaboli te of vecuronium, 3-désacetyl-vecuronium(Or-g 7268), was much less pronouncecl.
The hypothesis that the interaction between muscle relaxants of the same group, i .e.
aminosteroids, is addit ive, is supportecl by the results of this simulat ion study. The t ime
collrse of action of cornbinations of rapacuronium and vecuronium may be explained by theirPK-PD characterist ics. The active metaboli te of rapacuronium inÍ luences the t ime course of
action to a greater extent than the active metaboli t ;  of vecuronium.
rn chapter 8 the PK-PD relat ionship of the three mivacurium isomers (cis-cis, cis-tratts, anc1tr1lts-trottsl and their interaction are investigatecl. In particular, the tirne course of action of
mivacurium does not corelate with i ts rapid breakdown by plasma cholinesterase.
Fourteen patients between 25-55 years, unclergoing non-major surgery, ASA class I-II, wereincluded. All patients receivecl thiopentoneltèntanlUisoflurine/orllrrrb anaesthesia.
Neuromuscular block was monitorecl mechono*yógraphical ly uring , ingle twitch st imulat ion(0' I Hz). Mivacuriurn was adrninisterecl as a short-term infusion, -".on 1ïn; ar.", ion 4.j( l '0) min and dose 145 (33) Fg kg-t.  Arterial blood samples were obtainecl,  and plasma was
analysed by high pertbrmance liquicl clrromatography. Pharmacokinetic ancl pK-pD mocleling
rvas perfbrmed using an iterative two-stage Bayesian approach, assuming that the trars-trars
and cis-trans isomers are equally potent.
A PK-PD model with an effect compartment linked to plasma clicl not flt to the clata
satisfactorily' A model using an interstitial space compartment between plasma ancl efÍect
compartment fitted signitÏcantly better. Parameters [mean (E\CV)] of the best Íïtting moclel
were: kip0.374 mint 146vn), k. i  0.151 min-r (36vo),Ècro gg trg L-i  (2otn7, onoy 3.7 (2zvo).It is concluded that the PK-PD behaviour of mivacurium coulcl be described using a moclel
with an interstitial space compartment interposed between the plasma and effect
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the concentration decline in this interposed compartment and only indirectly related to the
rapid plasma clearance.
In chapter'9 diff-erent strategies to analyse PK-PD data are investigated.
Usually pharmacokinetic-pharmacodynamic (PK-PD) modeling is perfbrmed sequentially:
first the pharmacokinetic (PK) model parameters are estimated from the plasma concentration
data (PK analysis); then the parameters of the link model (if applicable) and the
pharmacodynamic model are estimated Írom the effect measurements and the PK parameters
(PD analysis). This approach is not ideal fiom a statistical point of view, because the
estimated PK parameters are treated as error-free constants in the PD analysis. These
statistical concerns may be satisfied using simultaneous PK-PD analysis of inclividual data by
maximisation of the joint likelihood of the PK and PD parameters. A method fbr simultaneous
PK-PD population analysis was developed using an Iterative Two-Stage Bayesian algorithm
and this technique was evaluated using clinical data of rocuronium as well as Monte Carlo
simulations.
Eleven patients (ASA class I-III) undergoing non-major surgery, aged between 20-64 years,
received thiopentone-fèntanyl-isoflurane-Oz-NzO anaesthesia. Neuromuscular block was
rnonitored mechanomyographically with single twitch stimulation (0.1 Hz). Rocuronium was
administered as a short-term infusion, mean (SD) duration 5.1 (1.0) min and dose 414 (89)
pg.kgt. Arterial blood samples were obtained and plasma was analysed by high perfbrmance
I iquid chromatography.
PK-PD parameters were estimated fiom nine evaluable patients by sequential analysis, PD
analysis from nonparametric PK data, and simultaneous analysis. Both Standard Two-Stage
analysis and Iterative Two-Stage Bayesian analysis were used for population analysis.
The design of the Monte Carlo simulation study was similar to that of the clinical study. In
total 1,000 population data sets of 9 patients each were generated by Monte Carlo simulation.
The accuracy and precision of the estimated model parameters were evaluated by comparing
their mean error and root mean squared eÍror. Also the inÍ-luence of the PD model
misspecification on the results was investigated.
The PK-PD population parameters and their interindividual variability were markedly
different between methods. In the Monte Carlo simulation, Iterative Two-Stage Bayesian
analysis performed better than Standard Two-Stage analysis. The simultaneous PK-PD
analysis resulted in slightly more precise population parameter estimates than the sequential
PK-PD analysis and the nonparametric PK method. In the presence of PD model
rnisspecification, simultaneous analysis resulted in poor PK parameter estimates, while
sequential PK-PD analysis performed better.
It is concluded that Iterative Two-Stage Bayesian analysis is a valuable technique for PK-PD
population analysis, and is superior to Standard Two-Stage analysis . Simultaneous PK-PD
analysis using Iterative Two-Stage Bayesian analysis was the most accurate and precise
method. However, in the presence of model misspecification the simultaneous analysis may
provide poor PK estimates. Therefore, the sequential PK-PD method using Iterative Two-
Stage Bayesian analysis is more suited for the analysis of real data.
In clnpter l0 general conclusions are made and future perspectives discussed.
Towards the ideal time course of neuromuscular blockade during surgery, combinations of
muscle relaxants are investigated and newer muscle relaxants have been developed.
Interaction between pharmacologically active molecules at the acetylcholine receptor of the
neuromuscular junction may occur as muscle relaxants are administered as mixtures of
isomers (kinship grade l), transformed into active metabolites (kinship grade 2) or given in a
combination of muscle relaxants (kinship grade 3 and 4).
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PK-PD analysis provides proper infbrmation about the dose-concentration-effect relationship
of these muscle relaxants and their mutual interaction. A sequential Bayesian PK-PD analysis
is the prefèrred strategy.
Nowadays not a single muscle relaxant is available that meets the criteria of rapid onset and
tlexible duration of action without unwanted effects. The aminosteroidal muscle relaxant
rocuronium offers an acceptable alternative if a non-depolarising rapid onset is preferred.
A f-lexible duration of action aÍter rocuronium administration may be created only by the
specific rocuronium antagonist, sugammadex. Sugarnmadex, a y-cyclodextrin, inactivates fiee
rocuronium molecules by encapsulat ion and is currently under cl inical investigation.
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